NMRA
insider transactionsNeumora Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-23.4K
0 buy · 23.4K sell
Net value · 365d
-$82.6K
$0 in · $82.6K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
4
0 buy · 23.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Sell·S
Joshua Pinto KEY
President
$21.1K
6.0K sh · $3.54
Own -9%
-
Sell·S
Title: Chief Financial Office… · 10b5-1
$5.1K
1.4K sh · $3.57
Own -6%
-
Sell·S
Paul L Berns KEY
Title: Chief Executive Office…
$34.5K
9.8K sh · $3.51
Own -0%
-
Sell·S
Title: Chief Operating and De…
$21.9K
6.2K sh · $3.56
Own -7%
-
Grant·A
Joshua Pinto KEY
President
$0
1.2M sh
Own New
-
Grant·A
Title: Chief Financial Office…
$0
350.0K sh
Own New
-
Grant·A
Title: Chief Legal and Admini…
$0
750.0K sh
Own New
-
Grant·A
Paul L Berns KEY
Title: Chief Executive Office…
$0
1.6M sh
Own New
-
Grant·A
Title: Chief Operating and De…
$0
750.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | David Piacquad | Grant A | 80.0K | $0 |
| May 27, 2026 | Alaa Halawa | Grant A | 80.0K | $0 |
| Feb 17, 2026 | Joshua Pinto KEY | Sell S | 6.0K | $21.1K |
| Feb 17, 2026 | Michael Lee Milligan KEY 10b5-1 | Sell S | 1.4K | $5.1K |
| Feb 17, 2026 | Paul L Berns KEY | Sell S | 9.8K | $34.5K |
| Feb 17, 2026 | Daljit Singh Aurora | Sell S | 6.2K | $21.9K |
| Jan 8, 2026 | Joshua Pinto KEY | Grant A | 1.2M | $0 |
| Jan 8, 2026 | Michael Lee Milligan KEY | Grant A | 350.0K | $0 |
| Jan 8, 2026 | Jason Duncan | Grant A | 750.0K | $0 |
| Jan 8, 2026 | Paul L Berns KEY | Grant A | 1.6M | $0 |
| Jan 8, 2026 | Daljit Singh Aurora | Grant A | 750.0K | $0 |
About NMRA insider trading
This page tracks insider transactions for Neumora Therapeutics, Inc. (NMRA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.